Shares of one biotechnology name drew fresh attention after new clinical data strengthened the outlook for its siRNA-targeting programs, according ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List Hot List Pro

Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)March 26, 2026 6:39 AM Sarepta Therapeutics (SRPT) PT Raised to $13 at CitiMarch 26, 2026 5:01 AM Barclays calls Sarepta Therapeutics (SRPT) data 'encouraging,' reiterates Equalweight ratingMarch 25, 2026 4:04 PM Sarepta Therapeutics (SRPT) PT Raised to $25 at Morgan StanleyMarch 25, 2026 3:05 PM BofA Securities stays Underperform on Sarepta Therapeutics (SRPT): data update 'directionally positive'March 25, 2026 3:02 PM Mizuho on Sarepta Therapeutics (SRPT): data de-risks siRNA platform, supports BIC potentialMarch 25, 2026 10:46 AM Wolfe Research stays Peerperform on Sarepta Therapeutics (SRPT) as data boosts RNA-focused narrativeMarch 25, 2026 10:43 AM Leerink Partners on Sarepta Therapeutics (SRPT): siRNA data 'a bit of a mixed bag'March 25, 2026 10:33 AM Jefferies sees '+15-30% stock move' for Sarepta Therapeutics (SRPT) following data March 25, 2026 10:32 AM Sarepta shares early clinical data from siRNA treatments for rare diseasesMarch 25, 2026 8:05 AM Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1March 25, 2026 8:05 AM